曼恩凯德生物医疗宣布,美国FDA已接受其Furoscix Readyflow™自动注射器的补充新药申请审查,该药物用于治疗慢性心力衰竭或慢性肾病成人的水肿。
曼恩凯德生物医疗宣布,美国FDA已接受其Furoscix Readyflow™自动注射器的补充新药申请审查,该药物用于治疗慢性心力衰竭或慢性肾病成人的水肿。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.